The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Featured:
Shaji KumarDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, How do response rates observed in clinical trials translate into real-world outcomes in multiple myeloma?
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Kumar discusses the characteristics of patients in clinical trials versus those treated in the real-world setting, highlighting the stringent inclusion/exclusion criteria and their impact on the generalizability of clinical trial results. He then explores how risk status, drug toxicity, and tolerability impact the real-world effectiveness of treatment. Kumar concludes by highlighting the differences between initial response rates seen in clinical trials and how this translates into longer-term outcomes, such as durability of response and progression-free survival.